FDA Orange Book · active-ingredient family
Atazanavir sulfate; cobicistat
Atazanavir sulfate; cobicistat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:EVOTAZ · NDA 206353
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| EVOTAZRLD | BRISTOL | NDA 206353 | — | Jan 29, 2015 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8148374 | Sep 03, 2029 | in 3 yr 3 mo | SubstanceProductU-1279 |
| 10039718 | Oct 06, 2032 | in 6 yr 5 mo | Product |
Atazanavir sulfate; cobicistat — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

